Operator

Ladies and gentlemen, welcome to the Coloplast conference Call. I am George, the Chorus Call operator. [Operator Instructions] The conference is being recorded. [Operator Instructions] Conference must not be recorded for publication or broadcast.

At this time, it's my pleasure to hand over to Lars Rasmussen, Interim CEO. Please go ahead, sir.

Lars Rasmussen
Interim CEO & President

Thank you very much. Good morning, and welcome to this extraordinary conference call on the back of the profit warning announced yesterday. I'm Lars Rasmussen, Interim CEO of Coloplast, and I'm joined by our CFO, Anders Lonning-Skovgaard, and our Investor Relations team. We will start with a short presentation by Anders and myself and then open up for questions.

Please turn to Slide #3. Yesterday, we revised our guidance for the full year '25/'26 and preannounced our results for the first half of '25/'26. Before addressing the drivers behind the guidance revision, I want to emphasize that we delivered a very strong quarter, excluding wound and tissue repair with solid underlying performance across the majority of the group. Chronic Care delivered a strong quarter with a pickup in momentum in Ostomy Care, as expected and continued good momentum in both Continence Care and Voice & Respiratory